News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Crucell N.V. Q2 Net Loss Narrows, Margin Disappoints
August 12, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
AMSTERDAM, Aug 12 (Reuters) - Dutch biotechnology firm Crucell's net loss halved in the second quarter, beating expectations, thanks to its key childhood vaccine product Quinvaxem, though gross margins disappointed.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Collaboration
Argenx Makes $1.5B+ Play for UNP’s Macrocyclic Peptides Aimed at ‘Undruggable’ Targets
July 1, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies
June 30, 2025
·
2 min read
·
Dan Samorodnitsky
Layoffs
BMS Continues New Jersey Layoffs, Bringing Yearly Total to Nearly 900
June 30, 2025
·
1 min read
·
Angela Gabriel
Alzheimer’s disease
Alzheimer’s Deals Surged 780% After Leqembi, Kisunla Broke Approval Stalemate
June 30, 2025
·
2 min read
·
Annalee Armstrong
